Patients with esophagogastric cancer have poor prognoses in spite of the best available therapies. Patients are debilitated and may not tolerate, or may progress, on standard cytotoxic chemotherapy regimens. Metronomic chemotherapy is an attractive treatment option due to its very low reported toxicity, modest efficacy, low cost and ease of administration. Capecitabine is the most common drug used in metronomic scheduling; other drugs include cyclophosphamide and paclitaxel. Dosing of capecitabine can range from 1000 mg orally daily for 4 weeks on and 1 week off to a continuous dosing schedule of 1500 mg orally daily.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k1ugJ8
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2o7K1Dm via IFTTT
-
AP ® United States Government and Politics 2014 Free-Response Questions © 2014 The College Board. College Board, Advanced Placement Program,...
-
You know the feeling: you're hanging out somewhere, you look across the room, and suddenly your stomach drops. You start to sweat. Your ...
-
Unit 5: Writing cohesively - Section index. This unit looks at the use of language strategies to create clear, cohesive writing. It shows yo...
-
Introduction Crisis management is a critical organizational function. Failure can result in serious harm to stakeholders, losses for an orga...
-
918 quotes have been tagged as self-confidence: Edgar Allan Poe: ‘I have great faith in fools - self-confidence my friends will call it.’, R...
-
Abstract This randomized and longitudinal in vivo study aimed to assess different protocols for the treatment of dentin hypersensitivity w...
-
About IRF. The Incentive Research Foundation (IRF), a private not-for-profit foundation, funds research studies and develops products servin...
-
9781421620831 1421620839 Coral Reef 2008 Square Wall - Wall 9780160782732 0160782732 Code of Federal Regulations, Title 27, Alcohol, Tobacco...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου